Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
FDA approves vutrisiran to treat ATTR-CM
The subcutaneous drug, sold under the brand name Amvuttra, joins an ATTR-CM market that already includes Pfizer’s tafamidis (Vyndaqel, Vyndamax) and BridgeBio’s acoramidis (Attruby).
Direct marketing to cardiologists increases uptake of some, but not all, heart failure drugs
Researchers tracked three years of CMS data to explore how meal-based marketing may influence the habits of general and advanced heart failure cardiologists.
Cannabis use increases risk of heart attack, stroke in young adults
“Asking about cannabis use should be part of clinicians' workup to understand patients' overall cardiovascular risk, similar to asking about smoking cigarettes,” one researcher said. Additional details will be presented at ACC.25 in Chicago.

New guideline on mechanical circulatory support tackles device selection, ethical dilemmas and more

The Heart Failure Society of America and International Society for Heart and Lung Transplantation worked together on the document, hoping their recommendations serve as a "critical roadmap" for clinicians.

More than a feeling? Social isolation, loneliness linked to a higher heart failure risk

A new study published in JACC: Heart Failure offers more evidence that a patient's feelings can strongly influence their risk of poor cardiovascular health.

CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company.

FDA announces new IABP recall after 4 serious injuries, 1 death

The new recall includes nearly 4,500 devices. There have been 134 incidents so far, including 5 adverse events.

An example if an implantable cardioverter defibrillator (ICD and its leads connected to the heart. As the leads or deveice wears out, there are recommendations to remove the leads and put in new ones. Image courtesy of RSNA

Infection, heart failure the most common reasons for early mortality after transvenous lead removal

Early mortality specifically related to complications during the TLR procedure was quite rare.

Medicare update designed to help heart failure patients may have the opposite effect

When Medicare made it easier for heart failure patients to receive a LVAD at a hospital that does not perform heart transplants, the change was intended to improve patient access. It turns out, however, that the policy shift could be linked to an unintended consequence.

Why cardiologists should pay close attention to rehospitalizations after TAVR or SAVR

A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.

The Dexcom G7 Continuous Glucose Monitoring System

Regulatory Roundup: FDA news on omecamtiv mecarbil for HFrEF, 'world's smallest heart pump' and more

Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed.

Heart Failure

Quality of care for heart patients does not improve in first year of ACO participation

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

FDA approves vutrisiran to treat ATTR-CM

Direct marketing to cardiologists increases uptake of some, but not all, heart failure drugs

Cannabis use increases risk of heart attack, stroke in young adults